Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

RootPath Raises $11 Million for Personalized TCR/CAR-T Solid Tumor Treatments

publication date: Jan 8, 2020

RootPath, a Cambridge, MA biotech with two R&D sites in China, closed an $11 million Series A round to develop a platform that identifies highly personalized tumor-reactive T cell receptors (TCRs) for solid tumor cancers. The company's Synthetic Immunology Platform™ uses ultrahigh-throughput screening to generate and select TCRs that become personalized T cell therapies and will be affordable for individuals or small groups. RootPath believes its technology, which combines precision medicine with immunotherapy, will make cell therapies effective in solid tumor cancers. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital